OCUL Ocular Therapeutix Inc
Price (delayed)
$7.34
Market cap
$1.17B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.22
Enterprise value
$849.29M
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation
Highlights
The revenue has grown by 9% YoY and by 3.7% from the previous quarter
Ocular Therapeutix's gross profit has increased by 9% YoY and by 4.4% QoQ
Ocular Therapeutix's quick ratio has surged by 61% YoY but it has decreased by 18% QoQ
The company's EPS fell by 21% YoY but it rose by 8% QoQ
The net income has dropped by 140% year-on-year and by 11% since the previous quarter
The equity has declined by 10% since the previous quarter
Key stats
What are the main financial stats of OCUL
Market
Valuations
Earnings
Shares outstanding
159.02M
Market cap
$1.17B
Enterprise value
$849.29M
Price to earnings (P/E)
N/A
Price to book (P/B)
3.66
Price to sales (P/S)
18.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.33
Revenue
$63.72M
Gross profit
$58.1M
Operating income
-$171.78M
Net income
-$193.51M
EBIT
-$179.93M
EBITDA
-$176.14M
Free cash flow
-$135.97M
Per share
Balance sheet
Liquidity
EPS
-$1.22
EPS diluted
-$1.22
Free cash flow per share
-$0.86
Book value per share
$2.01
Revenue per share
$0.4
TBVPS
$2.89
Total assets
$457.94M
Total liabilities
$142.59M
Debt
$75.78M
Equity
$315.34M
Working capital
$399.63M
Debt to equity
0.24
Current ratio
10.66
Quick ratio
10.3
Net debt/EBITDA
1.8
Margins
Efficiency
Dividend
EBITDA margin
-276.4%
Gross margin
91.2%
Net margin
-303.7%
Operating margin
-269.6%
Return on assets
-38.6%
Return on equity
-53.3%
Return on invested capital
-178.1%
Return on capital employed
-43.2%
Return on sales
-282.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
OCUL stock price
How has the Ocular Therapeutix stock price performed over time
Intraday
12.23%
1 week
-4.3%
1 month
2.8%
1 year
-13.44%
YTD
-14.05%
QTD
0.14%
Financial performance
How have Ocular Therapeutix's revenue and profit performed over time
Revenue
$63.72M
Gross profit
$58.1M
Operating income
-$171.78M
Net income
-$193.51M
Gross margin
91.2%
Net margin
-303.7%
The net income has dropped by 140% year-on-year and by 11% since the previous quarter
The net margin has plunged by 120% YoY and by 7% from the previous quarter
The operating income has plunged by 109% YoY and by 22% from the previous quarter
Ocular Therapeutix's operating margin has plunged by 91% YoY and by 17% from the previous quarter
Growth
What is Ocular Therapeutix's growth rate over time
Valuation
What is Ocular Therapeutix stock price valuation
P/E
N/A
P/B
3.66
P/S
18.23
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.33
The company's EPS fell by 21% YoY but it rose by 8% QoQ
OCUL's price to book (P/B) is 85% less than its 5-year quarterly average of 21.7 and 9% less than its last 4 quarters average of 3.6
The equity has declined by 10% since the previous quarter
The stock's P/S is 29% below its 5-year quarterly average of 22.8 and 22% below its last 4 quarters average of 20.9
The revenue has grown by 9% YoY and by 3.7% from the previous quarter
Efficiency
How efficient is Ocular Therapeutix business performance
The company's return on sales has shrunk by 138% YoY and by 9% QoQ
OCUL's return on invested capital has dropped by 137% year-on-year and by 14% since the previous quarter
Ocular Therapeutix's return on equity has surged by 82% YoY and by 6% QoQ
The return on assets has grown by 20% year-on-year
Dividends
What is OCUL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for OCUL.
Financial health
How did Ocular Therapeutix financials performed over time
Ocular Therapeutix's total assets has surged by 82% YoY but it has decreased by 7% QoQ
Ocular Therapeutix's quick ratio has surged by 61% YoY but it has decreased by 18% QoQ
The debt is 76% less than the equity
The company's debt to equity has shrunk by 74% YoY but it rose by 14% QoQ
The equity has declined by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.